Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stocks Market Movement: Palantir surged on October 8 as Goldman Sachs upgraded its rating, sovereign AI demand increased, and enterprise AI software gained attention.

US Stocks Market Movement: Palantir surged on October 8 as Goldman Sachs upgraded its rating, sovereign AI demand increased, and enterprise AI software gained attention.

Bitget异动解读Bitget异动解读2026/10/08 13:40
Show original

Palantir Surges on October 8: Analysis

Keywords: Goldman Sachs rating upgrade, sovereign AI demand, enterprise AI software

1. On October 8, Goldman Sachs upgraded Palantir's rating from "Neutral" to "Buy" and set a target price of $230, citing reasons including growth in sovereign AI and customized software demand as well as a verticalized sales strategy.

2. On October 8, Yorkville Ives initiated coverage of Palantir with an "Outperform" rating and a $250 target price, stating that its Foundry, Gotham, Apollo, and AI platforms are becoming the foundational operational layer for enterprise and government AI deployment.

3. On October 7, Palantir and Armada announced their collaboration to provide sovereign AI in modular data centers in the United States and allied countries, enabling government and enterprise clients to run open-weight models within their own security boundaries.

(Disclaimer: This content is generated by AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Market Movements | Biotechnology Sector Generally Declines, Merck (MRK.US) Drops Over 2%

According to Zhitong Finance APP, on Thursday, the biotechnology sector broadly declined. Eli Lilly (LLY.US) dropped over 3%, Merck (MRK.US) fell more than 2%, Johnson & Johnson (JNJ.US) declined 2%, Novo Nordisk (NVO.US) and AbbVie (ABBV.US) both dropped over 1%.

智通财经•2026/10/08 15:06